Dupixent’s success across eight indications is a model other drugmakers would like to replicate. R&D leaders at Sanofi and Regeneron reflect back on the development strategy that built the $15bn product.
Deal Snapshot: Hengrui makes its third potential billion-dollar licensing deal of 2025, this time sending rights to Phase III hypertrophic cardiomyopathy drug HRS-1893 to Braveheart.
The companies announced the publication of Phase III data that they said provide rationale for moving forward in a confirmatory trial.
The Swiss neuroscience specialist has extended its cash runway into late 2027, but will still need positive readouts in the coming months, including for its wholly owned Parkinson’s candidate.
Amgen and Zai Lab said the final analysis of the FORTITUDE-101 trial showed a decreased magnitude of OS benefit in first-line gastric cancer.
The Phase II study tested AP-101 safety and tolerability as the primary endpoint but showed “clinically meaningful” efficacy in exploratory endpoints.
Public Company Edition: The US jobs report for August hurt the S&P 500 and Dow Jones, but the XBI rose 2.2% and is up 6% year-to-date. Despite signs of life, with a recent small IPO from Curanex and a larger one proposed by LB Pharmaceuticals, fundraising was down in Q2.
Deal Snapshot: Hengrui makes its third potential billion-dollar licensing deal of 2025, this time sending rights to Phase III hypertrophic cardiomyopathy drug HRS-1893 to Braveheart.
Seizing an opportunity to buy out struggling 'zombie' biotechs, Xoma is helping to return investor cash and pick up potential bargain assets for itself. Its CEO and chief investment officer explained their approach to Scrip.
OMass Therapeutics has signed its debut licensing deal with Roche’s Genentech unit. Its CEO Rosamond Deegan talked to Scrip about what drew Roche’s interest to the preclinical IBD program, the company’s lead assets and the potential for other deals.
Public Company Edition: The US jobs report for August hurt the S&P 500 and Dow Jones, but the XBI rose 2.2% and is up 6% year-to-date. Despite signs of life, with a recent small IPO from Curanex and a larger one proposed by LB Pharmaceuticals, fundraising was down in Q2.
Recent moves in the industry include C-suite changes at Mitsubishi Tanabe Pharma and Oculis Holding, plus clock.bio gets a new chief business officer from BioNTech.
Private Company Edition: Treeline will fund Phase I trials for at least four cancer drugs with its $200m series A extension. Also, allogeneic CAR-T developer Wugen raised $115m, CHARM Therapeutics garnered $80m in series B cash and Plexium disclosed a $60.1m financing.
The first approved anti-PD-1 antibody to market eased ahead of later entrants by sales. But efficacy, tolerability and ease of administration are factors that count beyond first-mover advantage.
